Inify Laboratories AB — Earnings Release 2025

Oct 29, 2025

Correction - Inify Laboratories: First gastrointestinal diagnoses delivered and UK clinical operations on track for launch early 2026

Correction - Inify Laboratories: First gastrointestinal diagnoses delivered and UK clinical operations on track for launch early 2026

In connection with the publication of the company's Q3 2025 Financial Report, it

was discovered that the amount for personnel costs in the parent company's

income statement was incorrect. The company is therefore making a correction to

the parent company's income statement.

STOCKHOLM - October 29, 2025 - Inify Laboratories, a unique laboratory service

that provides cancer diagnostics within pathology, expanded its service offering

during the third quarter with the addition of a second diagnostic area:

gastroenterology. In September, the company launched gastrointestinal

diagnostics services in Sweden, successfully diagnosing its first patient

samples.

"This marks the starting point for addressing a market with very large sample

volumes and enormous capacity needs. In Sweden alone, hundreds of thousands of

endoscopy examinations are performed annually, many of which result in tissue

sampling," says CEO Fredrik Palm of Inify Laboratories.

Sales growth in the third quarter was strong, with an increase of 76% compared

to the corresponding period last year, and 78% for the period January -

September. The subsidiary Inify Laboratories Nordics continues to support

expansion with its steady positive cashflow. Cash balance at the end of the

period amounted to SEK 112 million.

The sales growth from gastrointestinal diagnostics is expected to build

gradually from 2026 onwards.

Construction of Inify's laboratory in Milton Park, just south of Oxford in the

UK, is progressing according to plan. The goal of launching clinical operations

in early 2026 remains unchanged. Dialogues with customers - primarily the NHS -

also continue to progress steadily.

"We remain optimistic that agreements will be signed, enabling sales to commence

through our UK subsidiary in close connection with the opening of the new

laboratory," says Palm.

Inify's initial UK offering will focus on prostate cancer diagnostics, where

most customer dialogues are already well advanced. Following the launch of

gastrointestinal diagnostics in Sweden, the company will gradually introduce

this area into the UK operations.

"Continued growth, expansion into a new diagnostic area, progress in our UK

establishment, and clear examples of the potential in our standardised and

structured data - all of this, in my view, bodes well for a bright and exciting

future, with Inify taking on an increasingly prominent role in current and

future healthcare," says Palm.

For further information, please contact CEO Fredrik Palm,

fredrik.palm@inify.com, or visit https://www.inify.com

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in

histopathology, with a focus on streamlining patient pathways. The company

performs clinical diagnostics in prostate cancer and gastroenterology, providing

an integrated service that spans from early sample handling to final diagnosis.

The laboratory system is scalable both in handling large volumes of patient

samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to

tissue preparation and diagnosis - using a fully digital, standardised and AI

-assisted workflow. The diagnosis is always performed by a pathologist and is

assisted by Inify's proprietary AI, proven to have world-leading precision in

clinical evaluations. The entire workflow is supported by a tailor-made system

that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Solna, Sweden,

with local laboratories in Sweden and the UK. The company's share is listed on

Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103

-MERK) under the ticker

INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)